Murine CD19 chimeric antigen receptor T-cell(CAR-T)products have been approved for the treatment of refractory/relapsed(R/R)B-cell acute lymphocytic leukemia(B-ALL); moreover, humanized products are also undergoing clinical trials. Here, CD19 is linked to acute lymphoblastic leukemia.